2005 Formulas for Verification of Foreign Patented Drug Prices

France

  • FP given in SEMPEX in euros
  • FP (reported in the formulary under column “Px–Achat”) is directly comparable to the PP reported by the patentee
  • The WP is derived as follows:
If: FP ≤ 22.90 WP = FP/1.1030
22.90 < FP ≤ 150.00 WP = 20.76 + (FP − 22.90)/1.06
FP > 150.00 WP = 140.66 + (FP − 150)/1.02
  • No price comparable to the HP reported by the patentee

Germany

  • FP given in Rote Liste in euros
  • FP includes 16% VAT; FPN = FP/1.16

Prescription Drugs

  • PP = (FPN - 8.10)/1.03
  • The WP is derived as follows:
If: 0 < PP ≤ 3.45 WP = PP/1.15
3.45 < PP ≤ 4.19 WP = PP − 0.45
4.19 < PP ≤ 5.60 WP = PP/1.12
5.60 < PP ≤ 7.26 WP = PP − 0.60
7.26 < PP ≤ 9.81 WP = PP/1.09
9.81 < PP ≤ 12.37 WP = PP − 0.81
12.37 < PP ≤ 24.61 WP = PP/1.07
24.61 < PP ≤ 28.43 WP = PP − 1.61
28.43 < PP ≤ 1,272.00 WP = PP/1.06
PP > 1,272.00 WP = PP − 72
  • No price comparable to the HP reported by the patentee

OTC Drugs

  • The PP is derived as follows:
If: FPN ≤ 2.04 PP = FPN/1.68
2.04 < FPN ≤ 2.16 PP = FPN − 0.8296
2.16 < FPN ≤ 6.28 PP = FPN/1.62
6.28 < FPN ≤ 6.62 PP = FPN − 2.4056
6.62 < FPN ≤ 11.4 PP = FPN/1.57
11.40 < FPN ≤ 12.8 PP = FPN − 4.161
12.80 < FPN ≤ 17.90 PP = FPN/1.48
17.90 < FPN ≤ 19.30 PP = FPN − 5.8272
19.30 < FPN ≤ 27.7 PP = FPN/1.43
27.70 < FPN ≤ 30.90 PP = FPN − 8.3506
30.90 < FPN ≤ 42.40 PP = FPN/1.37
42.40 < FPN ≤ 49.20 PP = FPN − 10.78
49.20 < FPN ≤ 707.08 PP = FPN/1.303
FPN > 707.08 PP = (FPN−118.24)/1.08263
  • The WP is derived as follows:
If: 0 < PP ≤ 1.01 WP = PP/1.21
1.01 < PP ≤ 1.05 WP = PP − 0.1764
1.05 < PP ≤ 2.04 WP = PP/1.20
2.04 < PP ≤ 2.08 WP = PP − 0.34
2.08 < PP ≤ 3.05 WP = PP/1.195
3.05 < PP ≤ 3.12 WP = PP − 0.4992
3.12 < PP ≤ 4.34 WP = PP/1.19
4.34 < PP ≤ 4.44 WP = PP − 1.69
4.44 < PP ≤ 7.14 WP = PP/1.185
7.14 < PP ≤ 7.31 WP = PP − 1.11555
7.31 < PP ≤ 10.70 WP = PP/1.18
10.70 < PP ≤ 12.60 WP = PP − 1.638
12.60 < PP ≤ 51.10 WP = PP/1.15
51.10 < PP ≤ 62.20 WP = PP − 6.67
62.20 < PP ≤ 766.93 WP = PP/1.12
PP > 766.93 WP = (PP − 61.63)/1.03
  • No price comparable to the HP reported by the patentee

Italy

  • FP given in l'Informatore Farmaceuticoin euros
  • FP includes a 10% VAT; FPN = FP/1.10
  • PP = FPN x 0.733
  • WP = FPN x 0.6665
  • No price comparable to the HP reported by patentee

Sweden

  • FP given in Prislista in Swedish kronas
  • The PP is derived as follows:
If: FP ≤ 119.0 PP = (FP − 29.25)/1.20
119.00 < FP ≤ 350.90 PP = (FP − 42.00)/1.03
350.90 < FP ≤ 6,164.9 PP = (FP − 45.00)/1.02
FP > 6,164.9 PP = FP − 165.00
  • The WP is derived as follows:
If: FP ≤ 119.0 WP = (FP − 29.25)/(1.20 x 1.032)
119.00 < FP ≤ 350.90 WP = (FP − 42.00)/(1.03 x 1.032)
350.90 < FP ≤ 6,164.9 WP = (FP − 45.00)/(1.02 x 1.032)
FP > 6,164.9 WP = (FP − 165.0)/1.032
  • No price comparable to the HP reported by patentee

Switzerland

  • FP given in Switzerland formulary (Medwin website) in Swiss francs
  • FP is directly comparable to the WP reported by the patentee
  • No prices comparable to the HP and the PP reported by patentee

United Kingdom

  • FP given in the Monthly Index of Medical Specialties (MIMS) in UK pounds
  • FP is directly comparable to the PP reported by the patentee
  • WP = FP x 0.875
  • No price comparable to HP reported by patentee

United States

  • No regulated mark-Cups
  • Prices given in US dollars
  • The Direct Price is directly comparable to the PP and/or HP reported by the patentee
  • The Wholesale Acquisition Cost (WAC) price is directly comparable to the WP reported by the patentee
  • The Federal Supply Schedule (FSS) price has been required by the PMPRB since 1998 and included in IPC tests since 2000
Date modified: